Literature DB >> 9706045

Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers.

P Annaert1, J Van Gelder, L Naesens, E De Clercq, G Van den Mooter, R Kinget, P Augustijns.   

Abstract

PURPOSE: To investigate the role of carrier mechanisms in: [1] the polarized transport of the bis(pivaloyloxymethyl)- [bis(POM)-] ester prodrug of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] and [2] the directional secretion of its metabolites.
METHODS: Caco-2 monolayers were used to study the modulation effect of carriers on the transport of bis(POM)-PMEA and the efflux of intracellularly formed metabolites mono(POM)-PMEA and PMEA from the cells. The interaction of bis(POM)-PMEA and its metabolites with the efflux mechanisms present in Caco-2 monolayers was investigated by testing the effect of various concentrations of verapamil (30, 100, 300, microns) or indomethacin (10-500 microns) on transport and efflux.
RESULTS: Polarity in transport of bis(POM)-PMEA (50 micron) across Caco-2 monolayers was noted: transport of total PMEA [=bis(POM)-PMEA, mono(POM)-PMEA and PMEA] was significantly higher in basolateral (BL) to apical (AP) direction (14.5 +/- 0.4%) than transport in the opposite (AP to BL) direction (1.7 +/- 0.2%). This difference was reduced in a concentration dependent way when verapamil (0-100 microns) was included in both AP and BL incubation media. After loading the cells with bis(POM)-PMEA (100 micron) for 1 hr, studies on efflux of PMEA and mono(POM)-PMEA from the Caco-2 monolayers over a 3 hr period, revealed that both metabolites were preferentially secreted towards the AP compartment. Efflux of PMEA toward AP and BL compartments amounted to 14.6 +/- 1.1% and 5.3 +/- 0.4, respectively, of the initial intracellular amount of total PMEA, while efflux of mono(POM)-PMEA towards AP and BL compartments was limited to 2.3 +/- 0.1% and 0.5 +/- 0.1%, respectively. When 10 micron indomethacin was included in the AP incubation medium, efflux of PMEA was decreased to 7.8 +/- 0.3% and 3.3 +/- 0.3% towards the AP and BL compartments, respectively. The decrease in efflux by indomethacin was concentration-dependent up to 100 micron. Transepithelial transport of total PMEA was also reduced in the presence of 30 micron indomethacin, as reflected in smaller concentrations of PMEA and mono(POM)-PMEA in the acceptor compartment, irrespective of the transport direction.
CONCLUSIONS: The data obtained in this study suggest that bis(POM)-PMEA is substrate for a P -glycoprotein-like carrier mechanism in Caco-2 monolayers, while its metabolites mono(POM)-PMEA and PMEA are transported by a non-P-glycoprotein efflux protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706045     DOI: 10.1023/a:1011923420719

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

Review 2.  The use of cultured epithelial and endothelial cells for drug transport and metabolism studies.

Authors:  K L Audus; R L Bartel; I J Hidalgo; R T Borchardt
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2).

Authors:  P Annaert; R Kinget; L Naesens; E de Clercq; P Augustijns
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

4.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.

Authors:  P F Augustijns; T P Bradshaw; L S Gan; R W Hendren; D R Thakker
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

5.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.

Authors:  L Naesens; J Balzarini; N Bischofberger; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

Authors:  J Hunter; M A Jepson; T Tsuruo; N L Simmons; B H Hirst
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

7.  P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells.

Authors:  A Tsuji; T Terasaki; Y Takabatake; Y Tenda; I Tamai; T Yamashima; S Moritani; T Tsuruo; J Yamashita
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

8.  Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.

Authors:  H Saitoh; B J Aungst
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

9.  Polarized efflux of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers.

Authors:  G K Collington; J Hunter; C N Allen; N L Simmons; B H Hirst
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

View more
  5 in total

1.  Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.

Authors:  R L de Vrueh; E T Rump; E van De Bilt; R van Veghel; J Balzarini; E A Biessen; T J van Berkel; M K Bijsterbosch
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin.

Authors:  Hugues Chanteux; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.

Authors:  D A Parasrampuria; M V Lantz; L Z Benet
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

4.  Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2).

Authors:  W Kamm; J Hauptmann; I Behrens; J Stürzebecher; F Dullweber; H Gohlke; M Stubbs; G Klebe; T Kissel
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

5.  Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis.

Authors:  Markéta Šmídková; Alexandra Dvoráková; Eva Tloust'ová; Michal Česnek; Zlatko Janeba; Helena Mertlíková-Kaiserová
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.